Clinical trial Recruiting at 29 sites Interventional Ages 18 and up

Personalized PEEP and Prone Positioning in Severe ARDS

Official title: Assessment of the PEEP Responsiveness to Titrate End-expiratory Pressure and of the Need for Muscle Relaxation During Prone Positioning in Moderate-to-severe Acute Respiratory Distress Syndrome: A Master Protocol

Run by Assistance Publique - Hôpitaux de Paris · NCT06849570 · Data updated 2026-11-12

This trial tests whether tailoring PEEP levels and using prone positioning with or without muscle relaxation can improve outcomes for adults with severe ARDS in the ICU.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment1200 (estimated)
SponsorAssistance Publique - Hôpitaux de Paris
Academic / other
Locations29 sites (Aix-en-Provence and 28 other locations)
StatusRecruiting
StartedNovember 5, 2025
Main results expectedNovember 5, 2028
Study endsNovember 5, 2029
Registry record updatedAugust 28, 2026
Trial IDNCT06849570 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with invasive ventilation for ARDS in the ICU meeting Berlin criteria and hypoxemia thresholds, within specified time windows for randomizations.

Probably not a fit

Patients unlikely to benefit may include those without recruitable lung or those intolerant to prone positioning or neuromuscular blockade.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This master protocol investigates personalized strategies for mechanical ventilation in moderate-to-severe ARDS. It includes approaches to set PEEP based on individual recruitability and explores the role of prone positioning and neuromuscular blockade. The study uses a sequential randomization design to test minimal distension versus maximal recruitment strategies, combined with prone positioning and early or rescue neuromuscular blockade. Outcomes focus on whether patient-specific ventilation settings can improve oxygenation and survival while maintaining safety. The trial is conducted in French ICU centers under a centralized lead sponsor.

Why it matters

Potential benefit: If successful, patients may experience better oxygenation and potentially improved survival through more personalized ventilation and positioning strategies.

How similar studies have gone: Previous ARDS ventilation studies support low tidal volumes; this trial tests a novel, personalized PEEP and positioning approach, which is exploratory but builds on established principles.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Invasive mechanical ventilation within 96 hours of ICU admission and within 72 hours of tracheal intubation for first randomization and then within 72 hours of the first randomization for the second randomization
* Patients meeting the Berlin ARDS definition criteria with hypoxemia characterized as

  * for first randomization: PaO2/FiO2 ≤150 mmHg on a PEEP ≥5 cmH2O with FiO2≥0.6 while VT is 6 ml/kg Predicted Body Weight (PBW) and adequate sedation level to adjust mechanical ventilation settings
  * for second randomization: PaO2/FiO2 ≤150 mmHg on optimized ventilatory settings according to the first randomization, confirmed by two Arterial blood gas (ABG) analyses separated by an interval time of 4 hours and observed within 72 hours of the first randomization
* Informed consent signed:

  * by the patient
  * Or informed consent signed by a family members/trustworthy person if his condition does not allow him to express his consent by written as per L. 1111-6
  * Or in a situation urgently and in the absence of family members/trustworthy person, the patient can be enrolled. The consent to participate to the research will be requested as soon as the condition of the patient will allow him to consent.
* Health insurance coverage

Exclusion Criteria:

* Age \< 18 years
* Known pregnancy or breastfeeding
* Participation in another interventional studies as long as these studies do not interfere with the primary endpoint and the secondary safety objectives of PEPER, or being in the exclusion period at the end of a previous study.
* Intracranial pressure \> 30 mm Hg or cerebral perfusion pressure \< 60 mmHg
* Severe chronic respiratory disease requiring long-term O2 therapy or home mechanical ventilation (except Continuous positive arway pressure (CPAP)/ Bilevel positive airway pressure (BIPAP) used for sleep apnea syndrome)
* Chronic interstitial lung disease
* Continuous neuromuscular blockade infusion at enrolment
* Previous hypersensitivity or anaphylactic reaction to any NMBA
* Neuromuscular disease that may potentiate neuromuscular blockade or impair spontaneous ventilation: amyotrophic lateral sclerosis, Guillain-Barré syndrome, myasthenia gravis, upper spinal injury at level C5 or above
* Patients on ECMO or any technique of extracorporeal CO2 removal
* Sickle cell disease
* Actual body weight \>1 kg/cm of height
* Severe chronic liver disease defined as a Child-Pugh score of 12-15
* Pneumothorax at randomization
* Expected duration of mechanical ventilation \<48 hours
* Simplified acute physiology score SAPS II score \>75 at the time of enrolment or suffering from a disease with an estimated survival time of less than two months
* Decision to withhold life-sustaining treatment
* Patients deprived of freedom or under legal authority
* Unstable spine fracture

Where it's running

  • CH Aix
    Aix-en-Provence, France
    Recruiting
  • Hôpital Pellegrin
    Bordeaux, France
    Recruiting
  • CH Fleyriat
    Bourg-en-Bresse, France
    Recruiting
  • Cavale Blanche
    Brest, France
    Recruiting
  • CHU de Caen Normandie
    Caen, France
    Recruiting
  • Hôpital de Dieppe
    Dieppe, France
    Recruiting
Show 23 more locations
  • CHI Fréjus Saint Raphaël
    Fréjus, France
    Recruiting
  • Hôpital Raymond Poincaré AP-HP
    Garches, France
    Recruiting
  • CHU Grenoble
    Grenoble, France
    Recruiting
  • CH de Bicêtre
    Le Kremlin-Bicêtre, France
    Recruiting
  • CH du Mans
    Le Mans, France
    Recruiting
  • Croix Rousse
    Lyon, France
    Recruiting
  • Groupement Hospitalier Sud
    Lyon, France
    Recruiting
  • Hôpital Sait Joseph Saint Luc
    Lyon, France
    Recruiting
  • APHM CHU Nord
    Marseille, France
    Recruiting
  • La Timone
    Marseille, France
    Recruiting
  • Hôpital de Brabois
    Nancy, France
    Recruiting
  • CHU de Nantes
    Nantes, France
    Recruiting
  • Hopital de l'Archet 1
    Nice, France
    Recruiting
  • Hôpital Cochin AP-HP
    Paris, France
    Recruiting
  • Hôpital de La Pitié Salpetrière AP-HP
    Paris, France
    Recruiting
  • Hôpital Saint Louis
    Paris, France
    Recruiting
  • La Pitié Salpetriere hospital - AP-HP
    Paris, France
    Recruiting
  • Hôpital Charles Nicolle
    Rouen, France
    Recruiting
  • Hôpital Nord
    Saint-Etienne, France
    Recruiting
  • CMC Foch
    Suresnes, France
    Recruiting
  • Hôpital Bretonneau
    Tours, France
    Recruiting
  • Centre Hospitalier de Troyes
    Troyes, France
    Recruiting
  • Hôpital André Mignot
    Versailles, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.